You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歐康維視生物-B(01477.HK)2024年收益同比增長65.6%-70.5%
格隆匯 02-12 22:53

格隆匯2月12日丨歐康維視生物-B(01477.HK)公吿,董事會欣然宣佈集團截至2024年12月31日止年度若干未經審核營運數據及比較數據載列如下。截至2024年12月31日止年度收益4.08億元-4.2億元,同比增長65.6%-70.5%。2024年收益的大幅增長主要由於:(i)公司完成了對Alcon轉讓產品的收購及獲許可產品的授權引進,顯著提升公司的收益規模;(ii)公司於銷售其他眼科醫藥產品產生的收益大幅增加。

於報吿期間,轉讓產品及獲許可產品對公司的影響包括:(i)不僅豐富了集團的產品線,亦為集團帶來可觀的經濟效益,尤其是思然®等乾眼症相關產品;(ii)進一步提高了公司於眼科藥物領域的競爭地位,尤其是加強了公司於乾眼症領域的業務競爭力。在已有的大量經驗和市場份額的積累上,公司有能力提供更為全面及先進的治療方案,進一步滿足患者需求,並擴大集團的市場份額;(iii)通過優化資源配置及市場推廣策略,結合公司強大的商業化及本地化能力,轉讓產品及獲許可產品成為公司長期穩定的收入來源。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account